Wilhelmus Cm Groenhuysen Sells 27,576 Shares of Novocure Ltd (NASDAQ:NVCR) Stock

Novocure Ltd (NASDAQ:NVCR) CFO Wilhelmus Cm Groenhuysen sold 27,576 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $81.87, for a total value of $2,257,647.12. Following the completion of the sale, the chief financial officer now owns 97,179 shares in the company, valued at approximately $7,956,044.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Wilhelmus Cm Groenhuysen also recently made the following trade(s):

  • On Monday, November 11th, Wilhelmus Cm Groenhuysen sold 8,600 shares of Novocure stock. The shares were sold at an average price of $80.13, for a total value of $689,118.00.
  • On Tuesday, September 24th, Wilhelmus Cm Groenhuysen sold 7,992 shares of Novocure stock. The shares were sold at an average price of $80.63, for a total value of $644,394.96.
  • On Monday, September 16th, Wilhelmus Cm Groenhuysen sold 25,000 shares of Novocure stock. The shares were sold at an average price of $78.93, for a total value of $1,973,250.00.
  • On Thursday, September 12th, Wilhelmus Cm Groenhuysen sold 25,000 shares of Novocure stock. The shares were sold at an average price of $79.57, for a total value of $1,989,250.00.
  • On Monday, September 9th, Wilhelmus Cm Groenhuysen sold 25,000 shares of Novocure stock. The shares were sold at an average price of $80.83, for a total value of $2,020,750.00.

Shares of NASDAQ:NVCR traded up $1.56 on Friday, reaching $83.98. 690,467 shares of the company traded hands, compared to its average volume of 721,575. The business’s 50-day simple moving average is $75.35 and its 200 day simple moving average is $70.25. Novocure Ltd has a 52 week low of $26.02 and a 52 week high of $98.70. The stock has a market capitalization of $8.00 billion, a P/E ratio of -121.71 and a beta of 2.34. The company has a current ratio of 5.06, a quick ratio of 4.76 and a debt-to-equity ratio of 0.84.

Novocure (NASDAQ:NVCR) last announced its quarterly earnings data on Thursday, October 31st. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.07. Novocure had a negative return on equity of 18.45% and a negative net margin of 8.43%. The firm had revenue of $92.06 million for the quarter, compared to analysts’ expectations of $87.12 million. During the same period last year, the firm earned ($0.13) earnings per share. The company’s revenue for the quarter was up 42.2% compared to the same quarter last year. Sell-side analysts expect that Novocure Ltd will post -0.13 EPS for the current fiscal year.

A number of research firms recently commented on NVCR. Zacks Investment Research cut Novocure from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. BidaskClub raised Novocure from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. SunTrust Banks raised Novocure from a “hold” rating to a “buy” rating in a research note on Monday, July 29th. Oppenheimer increased their target price on Novocure from $85.00 to $97.00 and gave the company a “buy” rating in a research note on Friday, September 13th. Finally, TheStreet raised Novocure from a “d” rating to a “c-” rating in a research note on Friday, July 26th. Six analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $79.33.

Several large investors have recently made changes to their positions in the company. Great Lakes Advisors LLC grew its stake in shares of Novocure by 82.6% during the third quarter. Great Lakes Advisors LLC now owns 96,593 shares of the medical equipment provider’s stock valued at $7,223,000 after buying an additional 43,701 shares during the last quarter. Carillon Tower Advisers Inc. purchased a new stake in shares of Novocure during the third quarter worth about $42,825,000. Eagle Asset Management Inc. boosted its holdings in shares of Novocure by 436.0% during the third quarter. Eagle Asset Management Inc. now owns 817,914 shares of the medical equipment provider’s stock worth $61,163,000 after purchasing an additional 665,321 shares during the period. Kornitzer Capital Management Inc. KS purchased a new stake in shares of Novocure during the third quarter worth about $4,027,000. Finally, First Mercantile Trust Co. purchased a new stake in shares of Novocure during the third quarter worth about $83,000. 66.61% of the stock is currently owned by hedge funds and other institutional investors.

Novocure Company Profile

Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline.

Featured Story: 52-Week High/Low

Insider Buying and Selling by Quarter for Novocure (NASDAQ:NVCR)

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.